Human Immunology News Volume 4.19 | May 17 2016

The Adhesion G Protein-Coupled Receptor GPR56/ADGRG1 Is an Inhibitory Receptor on Human NK Cells
Investigators explored the regulation and function of GPR56/ADGRG1, an adhesion G protein-coupled receptor implicated in developmental processes and expressed distinctively in mature natural killer (NK) cells. [Cell Rep] Full Article | Graphical Abstract

Human Macrophages Induce CD4⁺Foxp3⁺ Regulatory T Cells via Binding and Re-Release of TGF-β
As a prerequisite for eventual translation of immunosuppressive macrophage (M2) therapy into clinical settings the authors studied the induction, stability and mechanism of generation of human induced Tregs by M2 macrophages generated with interleukin-4/interleukin-10/transforming growth factor-β (TGF-β). [Immunol Cell Biol] Abstract

BCR–ABL-Specific CD4⁺ T-Helper Cells Promote the Priming of Antigen-Specific Cytotoxic T Cells via Dendritic Cells
Scientists established a BCR–ABL p210 b3a2 fusion-region-specific CD4⁺ T-helper-cell clone and examined its dendritic cell-mediated antileukemic potential. [Cell Mol Immunol] Abstract

Redirecting T-Cell Specificity to EGFR Using mRNA to Self-Limit Expression of Chimeric Antigen Receptor
Researchers evaluated expression of an epidermal growth factor receptor (EGFR)-specific chimeric antigen receptor coded from introduced mRNA in human T cells numerically expanded ex vivo to clinically significant numbers through coculture with activating and propagating cells derived from K562 preloaded with anti-CD3 antibody. [J Immunother] Abstract

Increased Th17 Cells and IL-17A Exist in Patients with B Cell Acute Lymphoblastic Leukemia and Promote Proliferation and Resistance to Daunorubicin through Activation of Akt Signaling
Scientists assessed and observed a significantly increased frequency of Th17 cells and a drastically decreased frequency of Th1 cells in peripheral blood mononuclear cells and bone marrow mononuclear cells from newly diagnosed B-cell acute lymphoblastic leukemia patients compared with healthy donors. [J Transl Med] Full Article

Promoter H3K4 Methylation Dynamically Reinforces Activation-Induced Pathways in Human CD4 T Cells
Researchers have detailed the dynamics of genome-wide promoter H3K4me2 and H3K4me3 over a time course during activation of human naive and memory CD4 T cells. They demonstrated that changes to H3K4 methylation occur relatively late after activation and reinforce activation-induced upregulation of gene expression, affecting multiple pathways important to T-cell activation, differentiation and function. [Genes Immun] Abstract

Aberrant Expression of B7-H4 Correlates with Poor Prognosis and Suppresses Tumor-Infiltration of CD8⁺ T Lymphocytes in Human Cholangiocarcinoma
The authors investigated the expression of B7-H4 in patients with cholangiocarcinoma and its association with patient prognosis. The correlation between B7-H4 expression and CD4⁺ and CD8⁺ tumor-infiltrating lymphocytes was also investigated. [Oncol Rep] Abstract

Subscribe to our sister publications: Immunology of Infectious Disease News & Immune Regulation News!

Roles of Regulatory T Cells in Cancer Immunity
The authors address the current understanding of regulatory T cells (T_reg)-mediated immune suppressive mechanisms in cancer, the involvement of T_regs in cancer immunotherapy, and strategies for effective and tolerable T_reg-targeted therapy. [Int Immunol] Abstract

Visit our reviews page to see a complete list of reviews in the human immunology research field.

From our sponsor: Learn how HLA labs save resources with RoboSep™. Watch the webinar.

Bristol-Myers Squibb and AbbVie Announce European Commission Approval of Empliciti™ (Elotuzumab) for the Treatment of Multiple Myeloma in Adult Patients Who Have Received at Least One Prior Therapy
Bristol-Myers Squibb Company and AbbVie announced that the European Commission has approved Empliciti™ for the treatment of multiple myeloma as combination therapy with Revlimid^® and dexamethasone in patients who have received at least one prior therapy. [Bristol-Myers Squibb Company] Press Release

Nimbus Therapeutics Announces Closing of Gilead Sciences’ Acquisition of Nimbus Apollo, Inc., and Its Acetyl-CoA Carboxylase (ACC) Inhibitor Program
Nimbus Therapeutics announced the recent closing of Gilead Sciences, Inc.’s acquisition of Nimbus Apollo, Inc. and its ACC inhibitor program. [Nimbus Therapeutics] Press Release

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the human immunology community.

NEW Research Associate – Immunology and Cell Separation (STEMCELL Technologies Inc.)

NEW Technical Sales Representative (STEMCELL Technologies Inc.)

NEW Postdoctoral Research Fellow – Metastatic Microenvironment Immunology (Fred Hutchinson Cancer Research Center)

NEW Postdoctoral Position – Tumor Immunology (Memorial Sloan Kettering Cancer Center)

NEW Postdoctoral Position – Immunology (Saarland University)

NEW Postdoctoral Fellow – Allergy and Immunology (Northwestern University-Feinberg School of Medicine)

NEW Postdoctoral Research Associate – Immunology (Benaroya Research Institute at Virginia Mason)

Research Technologist – T Cell Immunology (STEMCELL Technologies Inc.)

Research Technologist – Cell Separation (STEMCELL Technologies Inc.)

Scientist – Bioengineering (STEMCELL Technologies Inc.)

Senior Scientist – Immunology and Cell Separation (STEMCELL Technologies Inc.)

Postdoctoral Fellowship – Immunology (Tongji Medical College)

Postdoctoral Fellow – Immunology (Technische Universität München)

Postdoctoral Fellow – Cancer Biology & Cancer Immunology (Fox Chase Cancer Center)

Faculty Positions – Microbiology and Immunology (National University of Singapore)

Postdoctoral Researchers – Tumor Immunology and Cancer Immunotherapy (University of California, Los Angeles)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.